NCT04568876View on ClinicalTrials.gov

Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Covid19
Interventions
DIETARY_SUPPLEMENT

Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension

Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes

COMBINATION_PRODUCT

Standard Therapy

Standard therapy established for individual patients

Trial Locations (1)

00189

Anestesia e Rianimazione Azienda Ospedaliera Universitaria Sant'Andrea, Roma

All Listed Sponsors
collaborator

"Azienda Ospedaliera Sant'Andrea"

OTHER

lead

Epitech Group SpA

INDUSTRY

NCT04568876 - Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients | Biotech Hunter | Biotech Hunter